<DOC>
	<DOC>NCT02547844</DOC>
	<brief_summary>To compare the lipidomic profile in patients with HIV-1 with viral suppression changing efavirenz + emtricitabine + tenofovir (Atripla) to rilpivirine + emtricitabine + tenofovir (Eviplera®) versus a group of patients that continue with Atripla®.</brief_summary>
	<brief_title>Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla</brief_title>
	<detailed_description />
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Patients aged 18 years or above Patients infected with HIV1 Patients treated with Atripla at least the last 6 months. Patients with virologic suppression (HIV RNA &lt;50 copies / ml) for at least the last 6 months. Women of childbearing potential must use contraception double barrier. Voluntary signature of informed consent Any acute or chronic (besides chronic HIV1) disease that could interfere with the analysis of lipidomic Women pregnant or lactating Abuse of alcohol or other drugs Body Mass Index (BMI)&gt; 25 Use of drugs that may affect lipid metabolism (lipidlowering drugs, steroids ...) Patients unable to understand the study protocol or any other condition that in the investigator's opinion could jeopardize compliance with the protocol History or presence of allergy to any of the study drugs or their components</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>